Session IV: Lymphoproliferative & Plasma Cell Myeloma Disorders
Tracks
Plenary Hall
| Friday, October 11, 2024 |
| 8:30 AM - 10:30 AM |
Speaker
Dr. Martin Hutchings
Senior Consultant, Dept. of Haematology, Rigshospitalet
Copenhagen University Hospital
HL, BV based vs Nivo based therapy in untreated cHL. Debate. (For BV based therapy)
8:30 AM - 8:45 AM
Prof. Andrew Davies
Professor of Haematological Oncology, University of Southampton
Director Southampton Cancer Research UK/ National Institutes of Health Research Experimental Cancer Medicines Centre
HL, BV based vs Nivo based therapy in untreated cHL. Debate (For Nivo based therapy)
8:45 AM - 9:00 AM
Dr. Christine Chen
Associate Professor, University of Toronto
Medical Director, Autologous Stem Cell Transplant Program, Division of Medical Oncology and Hematology, Medicine, Unive
Updates in the treatment of newly diagnosed Multiple Myeloma. Quadruplet vs Triplets?
9:10 AM - 9:30 AM
Dr. Martin Hutchings
Senior Consultant, Dept. of Haematology, Rigshospitalet
Copenhagen University Hospital
DLBCL: CAR T Cell or Bispecific antibodies therapy for Refractory/ Relapsed DLBCL. Debate (For Bispecific antibodies)
9:50 AM - 10:05 AM
Prof. Andrew Davies
Professor of Haematological Oncology, University of Southampton
Director Southampton Cancer Research UK/ National Institutes of Health Research Experimental Cancer Medicines Centre
DLBCL: CAR T Cell or Bispecific antibodies therapy for Refractory/ Relapsed DLBCL. Debate (For CAR T cell)
10:05 AM - 10:20 AMSession Chair
Khalil Al Farsi
Senior Consultant, Hematology/BMT, Department of Hematology
Sultan Qaboos University Hospital
Muna Al Tarshi
Senior Consultant - Hematology and Bone Marrow Transplant
The Royal Hospital
